Showing posts with label Medicis. Show all posts
Showing posts with label Medicis. Show all posts

Wednesday, April 17, 2013

Patent Litigation Resolved between Medicis and Actavis

On August 2012, Medicis filed a complaint against Actavis for infringing the patent US8236816. The patent is entitled ‘2.times.2.times.2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod’. The patent was issued in Aug 2012 and expires[i] in Dec 2029. The patent is currently assigned[ii] to Medicis (source: MaxVal’s Assignment Database).

The case was filed against Actavis for filing Abbreviated New Drug Application (ANDA) no. 203-792 and 202-564 for Clindamycin and Tretinoin Gel and Imiquimod Cream, seeking FDA approval to manufacture generic versions of Zyclara® and Ziana®.

Zyclara cream is used to treat actinic keratosis (a condition caused by too much sun exposure) on the face and scalp. Ziana is a gel used to treat severe nodular acne above 12 years.

Now Medicis (a subsidiary of Valeant) and Actavis have reached a settlement agreement. Under the terms of the agreement, Actavis may launch its generic versions of Zyclara® and Ziana® in July 2016 and Jan, 2019.

Actavis stated that Valeant will receive a share of the economics from the generic products sold under the agreements. No other information about the agreement is available at this time. The settlement agreement puts an end to the litigation between the parties.

For more details see 1:12-cv-01091. To get alerts on cases filed/closed, subscribe to our Litigation Alerts.

Has this patent been litigated? Use our free tool or download our free Android and iOS app on Google Play and iTunes App Store.


[i] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[ii] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.

Monday, December 10, 2012

Medicis Sues Alkem over Generic Version of Solodyn



Medicis (plaintiff) filed a complaint against Alkem, The Pharma Network and Ascend (defendants) in the U.S. District Court of Delaware (case no. 1:12-cv-01663) on Wednesday, December 05, 2012, for filing ANDA for generic version of Solodyn®. 

Medicis Pharmaceutical Corporation is a specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Their products include Solodyn and Ziana for treating acne. Alkem is in the business of manufacturing generic pharmaceutical drugs. The Pharma Network (TPN) is a wholly owned subsidiary of Alkem. Ascend markets pharmaceutical products including generic drugs manufactured by Alkem. 

The patents involved in this suit are

Patent Number
Current Assignee[i]
Issued Date
Expiration Date[ii]
Title

Jun 01, 1999
Feb 19, 2018
Method for the treatment of acne

Sep 07, 2010
Jun 24, 2025
Minocycline oral dosage forms for the treatment of acne

Sep 18, 2012
Jun 24, 2025
Minocycline oral dosage forms for the treatment of acne
Note: Table information sourced from Maxval’s Assignment Database and Litigation Database.

Medicis is the current holder[iii] of the New Drug Application (NDA) no. 050808 for Solodyn® (source: Maxval’s Patent Marker) that is approved by FDA. Solodyn® is a tetracycline antibiotic approved to treat pimples and red bumps occurring with moderate to severe acne in people above 12 years. The complaint is filed against the defendants for seeking FDA approval with the Abbreviated New Drug Application (ANDA) no. 204453 (the Alkem ANDA) to market a generic version of Solodyn® that infringes the above patents.  

Plaintiff has recently filed suit against the companies below:

Company
Case Number
Date Filed
Status
Sidmak
12/05/2012
Pending
Actavis
08/31/2012
Pending
Zydus
06/05/2012
Pending
If you are interested in knowing more about the cases filed by Medicis, please contact us.

For more details, visit MaxVal-IP and subscribe to our Litigation Alerts.


[i]MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[ii]Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[iii]Patent Marker provides an online environment for patentees to virtually mark products and search for patent related information.